NTLA- Intellia Therapeutics, Inc.

Name: Intellia Therapeutics, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Intellia Therapeutics, Inc. (NTLA) has 14 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. NTLA is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Leonard John M	1.01M	$14.47M	-
Dir	Cohen Fred E	207.5K	$2.96M	-
Dir	Chase William J	134.7K	$1.92M	-
VP	Lebwohl David	121.2K	$1.73M	-
VP	Basta James	101.5K	$1.45M	-

Activity

Buys and sells only

Transactions

10 filings · page 5

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Oct 31, 2023	Bhanji Muna62	Director	Sell	265	$23.90	$6,333.50	-2.2%	+4.5%	-42.8%
Jul 31, 2023	Bhanji Muna62	Director	Sell	265	$42.33	$11,217.45	-2.1%	-43.7%	-37.9%
Jul 6, 2023	Bhanji Muna62	Director	Sell	1,867	$39.30	$73,373.10	-13.0%	-26.0%	-41.8%
Jul 3, 2023	Clark Eliana78	EVP, Chief Technical Officer	Sell	360	$40.51	$14,583.60	-0.8%	-27.8%	-45.6%
Jun 20, 2023	Clark Eliana78	EVP, Chief Technical Officer	Sale+OE	5,000	$45.00	$225,000.00	-10.0%	-19.7%	-44.6%
Mar 2, 2023	Basta James72	EVP, General Counsel	Sell	1,088	$43.88	$47,741.44	-1.9%	-15.3%	-25.8%
Jan 5, 2023	Sepp-Lorenzino Laura83	EVP, Chief Scientific Officer	Sell	4,838	$37.82	$182,981.60	-8.0%	-7.7%	-26.2%
Jan 4, 2023	Lebwohl David87	EVP, Chief Medical Officer	Sell	2,574	$37.21	$95,778.54	-9.1%	-7.5%	-24.6%
Jan 4, 2023	Goddard Glenn83	EVP, Chief Financial Officer	Sell	2,427	$37.21	$90,308.67	-13.6%	-7.5%	-24.6%
Jan 4, 2023	Leonard John M83	President And CEO	Sell	6,673	$37.21	$248,302.33	-0.9%	-7.5%	-24.6%

← PrevPage 5Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC